Filing Flows › Neuroone Medical Technologies (NMTC) › Q4 FY24
Neuroone Medical Technologies (NMTC) Q4 FY24 earnings results (fourth quarter fiscal 2024)
10-K filed Dec 17, 2024
Neuroone Medical Technologies (NMTC) reported revenue of $272K for the fourth quarter fiscal 2024 (Q4 FY24), -63% from a year earlier and -67% from the quarter before.
Neuroone Medical Technologies, Q4 FY24: revenue $272K (-63% year over year), net loss $3.4M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q4 FY24 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $272K | -67% | -63% |
| Operating profit | −$2.8M | — | — |
| Net earnings | −$3.4M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $272K in Q4 FY24, down 63% year over year and down 67% from the previous quarter.
Gross margin was 51.8%, up 25.7 points from a year earlier. Operating costs exceeded revenue by $2.8M, an operating margin of -1034.5%. Operating expenses fell 12% while revenue fell 63%. The fastest-growing cost line was SG&A (+17%). The quarter ended with a net loss of $3.4M, wider than the previous quarter's $2.8M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $64K of depreciation and amortization and $340K of share-based compensation. Working capital and other items added $279K. Capital expenditures of $37K exceeded it, leaving free cash flow of −$2.7M.
Questions
What was Neuroone Medical Technologies' revenue in the fourth quarter fiscal 2024?
Neuroone Medical Technologies (NMTC) reported revenue of $272K for the fourth quarter fiscal 2024 (Q4 FY24), -63% from a year earlier and -67% from the quarter before.